Clinical Chemistry and Laboratory Medicine (CCLM)
Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Editor-in-Chief: Plebani, Mario
Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.
IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition
SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238
Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia
1First Department of Pediatrics, Semmelweis University, Budapest, Hungary
2Research Group of Pediatrics and Nephrology, Hungarian Academy of Sciences, Budapest, Hungary
3Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary
4First Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 11, Pages 1873–1876, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm.2011.656, July 2011
- Published Online:
Background: Preeclampsia is characterized by a maternal systemic inflammatory response and the impairment of maternal immune tolerance present in healthy pregnancy. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the monitoring of systemic inflammation. We aimed to assess the levels of suPAR and other markers of systemic inflammation in preeclampsia compared to healthy pregnancy.
Methods: We determined plasma suPAR, IL-6 and high sensitivity C-reactive protein (hs-CRP) levels in plasma samples of 62 healthy pregnant and 41 preeclamptic women in the third trimester of pregnancy.
Results: Plasma suPAR levels were elevated in preeclampsia [3.18 (2.30–4.71) ng/mL vs. 2.02 (1.81–2.40) ng/mL, p=0.0001, median (interquartile range)]. IL-6 and hs-CRP levels were also higher compared with healthy pregnancy [5.99 (2.97–18.12) pg/mL vs. 1.41 (1.00–2.70) pg/mL, p=0.0001 and 6.60 (3.55–15.40) mg/L vs. 3.90 (2.10–7.25) mg/L, p=0.006, respectively, median (interquartile range)]. Linear regression analyses revealed an association between individual plasma suPAR and log IL-6 levels as well as log hs-CRP levels.
Conclusions: suPAR levels are elevated in preeclampsia and vary in a narrower range compared with IL-6 and hs-CRP. ROC analysis indicated that monitoring of suPAR levels is a suitable tool for the detection of systemic inflammation in pregnancy.
Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.